文献速递产科母胎医学

血小板活化与胎盘介导的不良妊娠结局:阿司匹林对妊娠与生殖影响试验的辅助研究

Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial.
PubMed 文献 · Am J Obstet Gynecol · 2020-05-17

该辅助研究测量了1185名育龄女性孕前、孕12周和孕28周的血浆血小板因子4浓度,并对584名妊娠≥20周的女性分析结局。孕前血小板因子4最高三分位与复合不良产科结局(RR 2.36,95%CI 1.38-4.03)及妊娠期高血压疾病(RR 2.14,95%CI 1.08-4.23)风险增加相关。在安慰剂组中关联更强(RR 3.36,95%CI 1.42-7.93),阿司匹林组为RR 1.78(95%CI 0.90-3.50),提示阿司匹林可能减轻高风险。

要点

  • 孕前血小板因子4升高与胎盘介导不良结局风险增加相关。
  • 该关联在安慰剂组强于阿司匹林组,提示阿司匹林可能减轻风险。
  • 低剂量阿司匹林无应答者可能需要更高剂量或替代治疗。

核心结论

  • 孕前高浓度血小板因子4与胎盘介导的不良妊娠结局风险增加相关,尤其与妊娠期高血压疾病相关。
  • 阿司匹林可能减轻孕前血小板因子4较高女性发生这些结局的风险,但低剂量阿司匹林无应答者可能需要更高剂量或替代治疗。

研究设计与样本

  • 该研究为阿司匹林对妊娠与生殖影响试验的辅助研究,纳入1185名有血浆样本的育龄女性测量血小板因子4。
  • 在584名妊娠持续至少20周的女性中评估结局,血浆样本采集于孕前研究访视(随机分组前)、孕12周和孕28周。
  • 采用对数二项回归估计相对风险(RR)和95%置信区间(CI),并对选择偏倚加权及调整年龄、体重指数、教育、收入和吸烟。

主要发现

  • 随访期间95名女性发生复合不良产科结局,包括57例妊娠期高血压疾病、35例小于胎龄儿和6例胎盘早剥。
  • 孕前血小板因子4第三三分位较第一三分位与复合结局风险增加相关(RR 2.36,95%CI 1.38-4.03)。
  • 孕前血小板因子4第三三分位较第一三分位与妊娠期高血压疾病风险增加相关(RR 2.14,95%CI 1.08-4.23)。
  • 按治疗组分层,安慰剂组关联更强(第三三分位vs第一三分位:RR 3.36,95%CI 1.42-7.93),阿司匹林组为RR 1.78(95%CI 0.90-3.50)。

关键数值与推荐

  • 孕前血小板因子4第三三分位vs第一三分位与复合结局的RR为2.36(95%CI 1.38-4.03)。
  • 孕前血小板因子4第三三分位vs第一三分位与妊娠期高血压疾病的RR为2.14(95%CI 1.08-4.23)。
  • 安慰剂组孕前血小板因子4第三三分位vs第一三分位与复合结局的RR为3.36(95%CI 1.42-7.93)。
  • 阿司匹林组孕前血小板因子4第三三分位vs第一三分位与复合结局的RR为1.78(95%CI 0.90-3.50)。

临床怎么用

  • 孕前血小板因子4检测可能有助于识别胎盘介导不良妊娠结局高风险女性。
  • 对于孕前血小板因子4较高的女性,低剂量阿司匹林可能降低风险,但需注意无应答者可能需要更高剂量或替代治疗。

局限性

  • 该研究为观察性辅助分析,不能确定因果关系。
  • 样本量有限,部分关联的置信区间较宽。
  • 阿司匹林组中孕前血小板因子4与复合结局的关联无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platelet activation may play a role in the pathophysiology of placenta-mediated obstetrical complications, as evidenced by the efficacy of aspirin in preventing preeclampsia, but published data regarding the relationship between biomarkers for platelet activation and adverse obstetrical outcomes are sparse. In particular, it is unknown whether prepregnancy biomarkers of platelet activation are associated with adverse pregnancy outcomes. OBJECTIVE: This study aimed to determine the following: (1) whether maternal plasma concentrations of platelet factor 4 are associated with risk of placenta-mediated adverse obstetrical outcomes, and (2) whether these associations are modified by low-dose aspirin. STUDY DESIGN: This ancillary study included measurement of platelet factor 4 among 1185 of 1228 women of reproductive age enrolled in the Effects of Aspirin in Gestation and Reproduction trial with available plasma samples, with relevant outcomes assessed among 584 women with pregnancies lasting at least 20 weeks' gestation. We measured platelet factor 4 in plasma samples obtained at the prepregnancy study visit (before randomization to low-dose aspirin or placebo), 12 weeks' gestation, and 28 weeks' gestation. The primary outcome was a composite of hypertensive disorders of pregnancy, placental abruption, and small-for-gestational-age infant. We estimated the relative risks (RRs) and 95% confidence intervals (CIs) for the association between platelet factor 4 and the composite and individual outcomes at each time point using log-binomial regression that was weighted to account for potential selection bias and adjusted for age, body mass index, education, income, and smoking. To evaluate the potential effect modification of aspirin, we stratified the analyses by aspirin treatment assignment. RESULTS: During follow-up, 95 women experienced the composite adverse obstetrical outcome, with 57 cases of hypertensive disorders of pregnancy, 35 of small for gestational age, and 6 of placental abruption. Overall, prepregnancy platelet factor 4 was positively associated with the composite outcome (third tertile vs first tertile; relative risk, 2.36; 95% confidence interval, 1.38-4.03) and with hypertensive disorders of pregnancy (third tertile vs first tertile; relative risk, 2.14; 95% confidence interval, 1.08-4.23). In analyses stratified by treatment group, associations were stronger in the placebo group (third tertile vs first tertile; relative risk, 3.36; 95% confidence interval, 1.42-7.93) than in the aspirin group (third tertile vs first tertile; relative risk, 1.78; 95% confidence interval, 0.90-3.50). CONCLUSION: High concentrations of platelet factor 4 before pregnancy are associated with increased risk of placenta-mediated adverse pregnancy outcomes, particularly for hypertensive disorders of pregnancy. Aspirin may mitigate the increased risk of these outcomes among women with higher plasma concentrations of preconception platelet factor 4, but low-dose aspirin nonresponders may require higher doses of aspirin or alternate therapies to achieve obstetrical risk reduction.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Theilen LH, Campbell HD, Mumford SL, et al. Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial. Am J Obstet Gynecol. 2020. PMID: 32434001. doi:10.1016/j.ajog.2020.05.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。